The Department of Justice joined whistleblower litigation accusing
Omnicare of violating the federal False Claims Act for illegally
dispensing drugs to tens of thousands of patients in assisted living
facilities, group homes for people with special needs, and other
long-term care facilities.
According to a civil complaint filed in Manhattan federal court,
Omnicare would often assign new numbers to prescriptions after the
original prescriptions expired or ran out of refills.
The government said this enabled Omnicare to bill Medicare Medicaid,
and Tricare, which serves military personnel, for hundreds of
thousands of drugs, under what the company internally called
"rollover" prescriptions, from 2010 to 2018.
Many of the drugs were anticonvulsants, antidepressants and
antipsychotics and treated serious conditions such as dementia,
depression and heart disease, and sometimes had dangerous side
effects requiring supervision by doctors, the government said.
"A pharmacy's fundamental obligation is to ensure that drugs are
dispensed only under the supervision of treating doctors who monitor
patients' drug therapies," U.S. Attorney Geoffrey Berman in
Manhattan said in a statement.
"Omnicare put at risk the health of tens of thousands of elderly and
disabled individuals living in assisted living and other residential
long-term care facilities," he added.
The lawsuit seeks civil penalties and other damages.
CVS, one of the largest U.S. drugstore chains and pharmacy benefit
managers, said it did not believe the claims had merit, and that it
intended to defend itself in court.
[to top of second column] |
"We are confident that Omnicare's dispensing practices will be found
to be consistent with state requirements and industry-accepted
practices," the company said in a statement.
CVS, based in Woonsocket, Rhode Island, bought Omnicare in 2015 for
about $10.4 billion.
The government joined a lawsuit originally brought in June 2015 by
Uri Bassan, a pharmacist who worked for Omnicare in Albuquerque, New
Mexico.
It said Omnicare's compliance department had acknowledged the
dispensing problem internally two months earlier, when a regional
officer expressed concern in an email that its systems allowed
rollover prescriptions "without any documentation or pharmacist
intervention."
The False Claims Act lets whistleblowers sue on behalf of the
federal government, and share in recoveries.
Twenty-nine U.S. states and the District of Columbia are also named
as plaintiffs.
The cases is U.S. ex rel. Bassan v. Omnicare Inc, U.S. District
Court, Southern District of New York, No. 15-04179.
(Reporting by Jonathan Stempel in New York; Editing by Chizu
Nomiyama and Bill Berkrot)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|